Purdue Pharma said a decade ago its crush-resistant formulation of OxyContin would prevent opioid overdoses and deaths, but while the new formulation might have reduced abuse via injection or snorting, it does not appear to have contributed to fewer deaths or overdoses, according to an FDA panel of experts.
Crush-proof OxyContin doesn't seem to have cut OD, death rates
Sign up for Specialty Pharmacy SmartBrief
News affecting the specialty pharmacy industry
Get the intelligence you need: news and information that is changing your industry today, hand-curated by our professional editors from thousands of sources and delivered straight to your inbox.